Wenhao Xu

22PUBLICATIONS
57CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Sep 11, 2026
Clinical Outcomes, Treatment Patterns, and Molecular Heterogeneity of TFE3-Rearranged Renal Cell Carcinoma: A Multicenter Real-World Study.

|Aug 07, 2026
APOE+ macrophages and POSTN+CAFs form immune-exclusion niche driving immunotherapy resistance in clear-cell renal carcinoma.

|Jul 12, 2026
METTL5-mediated rRNA modification controls prostate cancer progression through the IRF7/DNA2 axis and mitophagy regulation.

|Jun 01, 2026
APOL3 Orchestrates Metastasis and Enzalutamide Resistance via STAT3-DAB2IP Signaling in Prostate Cancer.

|May 21, 2026
Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies.

|Nov 27, 2025
Polystyrene Microplastics Exposure Aggravates Clear Cell Renal Cell Carcinoma Progression via the NF-κB and TGF-β Signaling Pathways.

Shiqi Ye, Jianfeng Xiang, Siqi Zhou

Pageof 4

Frequent Collaborators

5 joint publications

Dingwei Ye

4 joint publications

Xi Tian

4 joint publications

Wangrui Liu

3 joint publications

Dingwei Ye